181 related articles for article (PubMed ID: 11443182)
41. Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women: a population-based study.
Khosla S; Atkinson EJ; Melton LJ; Riggs BL
J Clin Endocrinol Metab; 1997 May; 82(5):1522-7. PubMed ID: 9141544
[TBL] [Abstract][Full Text] [Related]
42. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
[TBL] [Abstract][Full Text] [Related]
43. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study.
Szulc P; Munoz F; Marchand F; Chapuy MC; Delmas PD
Calcif Tissue Int; 2003 Dec; 73(6):520-30. PubMed ID: 12958693
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
[TBL] [Abstract][Full Text] [Related]
45. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis.
González-Calvin JL; Mundi JL; Casado-Caballero FJ; Abadia AC; Martin-Ibañez JJ
J Clin Endocrinol Metab; 2009 Dec; 94(12):4844-50. PubMed ID: 19897681
[TBL] [Abstract][Full Text] [Related]
46. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
47. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis.
Yano K; Tsuda E; Washida N; Kobayashi F; Goto M; Harada A; Ikeda K; Higashio K; Yamada Y
J Bone Miner Res; 1999 Apr; 14(4):518-27. PubMed ID: 10234572
[TBL] [Abstract][Full Text] [Related]
48. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
Buxton EC; Yao W; Lane NE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
[TBL] [Abstract][Full Text] [Related]
49. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men.
Rucker D; Ezzat S; Diamandi A; Khosravi J; Hanley DA
Clin Endocrinol (Oxf); 2004 Apr; 60(4):491-9. PubMed ID: 15049965
[TBL] [Abstract][Full Text] [Related]
50. Serum levels of osteoprotegerin increase with age in a healthy adult population.
Kudlacek S; Schneider B; Woloszczuk W; Pietschmann P; Willvonseder R;
Bone; 2003 Jun; 32(6):681-6. PubMed ID: 12810175
[TBL] [Abstract][Full Text] [Related]
51. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
[TBL] [Abstract][Full Text] [Related]
52. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
Bashir A; Mak YT; Sankaralingam S; Cheung J; McGowan NW; Grigoriadis AE; Fogelman I; Hampson G
Steroids; 2005 Dec; 70(13):847-55. PubMed ID: 16005483
[TBL] [Abstract][Full Text] [Related]
53. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
[TBL] [Abstract][Full Text] [Related]
54. Increased osteoprotegerin serum levels in men with coronary artery disease.
Schoppet M; Sattler AM; Schaefer JR; Herzum M; Maisch B; Hofbauer LC
J Clin Endocrinol Metab; 2003 Mar; 88(3):1024-8. PubMed ID: 12629080
[TBL] [Abstract][Full Text] [Related]
55. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
56. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
57. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
58. Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.
Khosla S; Melton LJ; Atkinson EJ; O'Fallon WM
J Clin Endocrinol Metab; 2001 Aug; 86(8):3555-61. PubMed ID: 11502778
[TBL] [Abstract][Full Text] [Related]
59. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults.
Lanzi R; Losa M; Villa I; Gatti E; Sirtori M; Dal Fiume C; Rubinacci A
Eur J Endocrinol; 2003 Feb; 148(2):185-91. PubMed ID: 12590637
[TBL] [Abstract][Full Text] [Related]
60. Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels.
Uebelhart B; Herrmann F; Pavo I; Draper MW; Rizzoli R
J Bone Miner Res; 2004 Sep; 19(9):1518-24. PubMed ID: 15312253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
